Scientific Evidence

Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test

Jul 2022

Validation of the integration the 31-GEP testing with clinpath features for invidialized risk assessment of MSS, DMFS, and RFS.

Author: Jarell A, et al.

Publication: Journal of the American Academy of Dermatology

An objective fully automated Barrett’s risk prediction assay outperforms most pathologists in risk stratifying Barrett’s esophagus with low-grade dysplasia

May 2022

Conventional pathology review based on histology has limitations, and the TissueCypher BE risk assessment tool can improve the accuracy of prognosis.

Author: Khoshiwal AM, et al.

Publication: Podium presentation (695) at DDW 2022, San Diego

Efficacy and tolerability of therapies set under pharmacogenetic tools suggestions: A systematic review with meta-analysis about mood disorders

May 2022

This systematic review with meta-analysis aims to evaluate the utility of pharmacogenetic tests (PGT) in terms of efficacy and tolerability into the routine clinical treatment of mood disorders.

Author: Ielmini M, et al.

Publication: Psychiatry Res

An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia

Apr 2022

Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.

Author: Khoshiwal AM, et al.

Publication: Podium presentation (OP079) at ESGE 2022, Prague

Incorporating the 31-gene expression profile test stratifies survival outcomes and leads to improved survival compared to clinicopathologic factors alone: a surveillance, epidemiology and end results (SEER) program collaboration

Apr 2022

Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.

Author: Kurley S, et al.

Publication: Poster, presented at the 18th European Association of Dermato Oncology (EADO) Congress, Seville Spain, April 21-23 2022.

Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following MOHS micrographic surgery

Apr 2022

Prospective multicenter study showed that integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.

Author: Thorpe RB et al.

Publication: Journal of the American Academy of Dermatology

Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th edition staging

Apr 2022

DecisionDx-Melanoma data significantly stratified MSS in stage I, II, and III patients. This test has also demonstrated high specificity and NPV for melanoma-specific mortality (MSM).

Author: Wisco O, et al.

Publication: Melanoma Research

An objective fully-automated Barrett's risk prediction assay outperforms most pathologists in risk stratifying Barrett's esophagus with low-grade dysplasia

Apr 2022

Histological review of community-based LGD showed a high inter-observer variability with a signification number of cases classified as non-informative.

Author: Khoshiwal AM, et al.

Publication: Podium presentation (OP079) at ESGE 2022, Prague

Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: consensus from the skin cancer prevention working group

Mar 2022

Expert panel of 8 dermatologists from the Skin Cancer Prevention Working Group developed 6 concensus statements supporting the appropriate use of GEP testing.

Author: Farberg A, et al.

Publication: Dermatology and Therapy

Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients

Feb 2022

To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the DecisionDx-SCC assay, a prognostic 40-gene expression profile (40-GEP) test, was developed and validated.

Author: Borman S. et al.

Publication: Diagnostic Pathology

Using a 31-gene expression profile test to stratify patients with stage I–II cutaneous melanoma according to recurrence risk: update to a prospective, multicenter study

Feb 2022

The 31-GEP accurately identified patients with stage IB-II CM at low and high risk of melanoma relapse in a prospective, multicenter study. Identifying which tumors have the highest probability of recurrence or metastasis, despite negative SLN results can aid in earlier disease detection. 

Author: Podlipnik S, et al.

Publication: Cancers

Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study

Feb 2022

Final report from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits. Outcomes data included.

Author: Dillon LD, et al.

Publication: Current Medical Research and Opinion